Fewer GLP-1 Shots May Be Enough to Maintain Weight Loss for Some Patients, Study Finds

One of the questions patients ask most often after achieving their weight loss goal on semaglutide or tirzepatide: do I have to keep taking the full dose forever?

A new review published in early March 2026 and covered by the New York Times suggests the answer may be more nuanced than the standard “yes, GLP-1 is lifelong therapy” framing. A meaningful subset of patients maintained their weight loss after reducing injection frequency — from weekly to biweekly or even monthly shots — without significant regain.

Here is what the data shows, who this applies to, and what it means for the future of GLP-1 dosing.

What the Review Found

The review analyzed a small group of patients who had achieved significant weight loss on weekly GLP-1 injections and subsequently reduced their dosing frequency to every two weeks or monthly. A subset of these patients maintained their weight loss and metabolic improvements without returning to weekly dosing.

The finding is notable because it challenges the assumption that weekly dosing is the only effective maintenance strategy. If some patients can maintain on less frequent injections, the implications are significant: lower cost, fewer injections, and potentially improved long-term adherence for people who struggle with the commitment of weekly administration.

Why This Might Work for Some Patients

GLP-1 receptor agonists like semaglutide work by creating sustained receptor saturation in the brain, gut, and pancreas. At weekly dosing, serum levels are kept relatively stable throughout the week. At lower dosing frequency, there is more peak-to-trough variation — levels drop further before the next injection.

For patients who have lost significant weight and whose appetite regulation has been durably reset, this variation may be tolerable. The hypothesis is that long-term GLP-1 use changes appetite set points and food preference patterns in ways that partially persist even when drug levels drop — meaning some patients need less pharmacological support to maintain their new baseline.

This is consistent with observations from clinical practice: some patients report that their reduced appetite and changed relationship with food persist somewhat even when they miss doses or experience supply disruptions. For a subset of patients, these behavioral changes may be durable enough to support maintenance at lower dosing frequency.

Who This Applies To (and Who It Probably Doesn’t)

The key word in the review is “subset.” Not all patients maintained weight loss on reduced dosing. The patients most likely to succeed with reduced frequency appear to share some characteristics:

• They had achieved a stable weight plateau over an extended period (typically 12+ months) before attempting dose reduction
• They had made durable dietary and lifestyle changes during treatment — GLP-1 was not the only thing holding the weight off
• They were reducing frequency gradually under physician supervision, not stopping abruptly
• Their starting BMI was in the moderate obesity range (30–35) rather than severe obesity (BMI >40)

Patients who are still actively losing weight, who have not made substantive dietary changes, or who have a history of rapid regain after stopping medications are less likely to succeed with reduced dosing. For this group, weekly maintenance dosing remains the evidence-based standard.

What the Existing Literature Says About Stopping

It is worth putting this new review in context of what is already known. A January 2026 BMJ meta-analysis of 9,341 patients across 37 studies found that stopping GLP-1 medications entirely results in regain of approximately 1.8 pounds per month, with most patients returning to near-baseline weight within 18 months.

The key distinction is between stopping entirely and reducing frequency. The new review specifically examined frequency reduction, not discontinuation. Maintaining some GLP-1 receptor activation — even at lower frequency — appears to produce substantially different outcomes than stopping completely.

This is clinically important because full discontinuation is often driven by cost or inconvenience, both of which might be partially addressed by reduced dosing frequency if it proves effective.

The Cost Angle

If biweekly dosing can maintain outcomes for some patients, the cost implications are meaningful. Brand-name Wegovy at $1,350/month drops to roughly $675/month equivalent if dosed every two weeks. Compounded semaglutide at $299/month becomes approximately $150/month equivalent — making long-term maintenance substantially more financially accessible.

This matters because cost is consistently cited as the primary reason patients discontinue GLP-1 therapy. If dose-extended maintenance is validated in larger prospective trials, it could meaningfully improve adherence rates and long-term outcomes at the population level.

The Practical Takeaway

If you are on semaglutide or tirzepatide, have achieved a stable weight, and are considering reducing your dose or frequency: discuss it with your prescribing physician before making any changes. The decision should be driven by your individual trajectory, not by a news headline.

What the review does not support is unilateral self-reduction without medical supervision. The patients who did well with reduced dosing in the review were monitored closely, had clear criteria for reverting to weekly dosing if regain occurred, and were supported by an ongoing clinical relationship.

The right path for most patients remains: achieve target weight on full-dose weekly therapy, establish durable habits, then work with your provider on a structured trial of reduced frequency if appropriate. This is a decision to make together — not a shortcut to take on your own.

Remedy Meds offers ongoing physician supervision that supports exactly this kind of individualized dose management. Learn more at remedymeds.co.

Medical disclaimer: This article is for informational purposes only and does not constitute medical advice. Do not change your medication dosing without consulting your prescribing physician. Last updated: March 2026.